Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
- 18 years ago
QualityStocks
Sinovac Biotech, Ltd. (AMEX: SVA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Advances Near-Term Gold Production Strategy in Quebec’s Abitibi Belt
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid…
-
QualityStocksNewsBreaks – Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Completes 2026 Field Exploration Program at Cameron Project
Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. Powermax Minerals…
-
SS Innovations International Inc. (NASDAQ: SSII) Expands Robotic Cardiac Surgery Footprint with New Program at HCG Hospital in Ahmedabad
The program began with a robotic left internal mammary artery (“LIMA”) take-down performed by Dr.…